Compass Therapeutics Craters, FDA Pushes Survival-Trial Demand for Cancer Drug

Compass Therapeutics shares traded lower after FDA feedback created uncertainty around the timing and potential requirements for its tovecimig program. The feedback raises regulatory-development risk for the company and could delay the program's path forward, though no specific FDA requirements or timeline changes were disclosed.